We investigated the functional role of a conserved motif, F(x) 6 LL, in the membrane proximal C-tail of the human muscarinic M 1 (hM 1 ) receptor. By use of site-directed mutagenesis, several different point mutations were introduced into the C-tail sequence 423 FRDTFRLLL 431 . Wild-type and mutant hM 1 receptors were transiently expressed in Chinese hamster ovary cells, and the amount of plasma membrane-expressed receptor was determined by use of intact, whole-cell [ play a role in folding hM 1 receptors, which is necessary for exit from the ER. Using site-directed mutagenesis, we also identified amino acid residues at the base of transmembrane-spanning domain 1 (TM1), V 46 and L 47 , that, when mutated, reduce the plasma membrane expression of hM 1 receptors in an atropine-reversible manner. Overall, these mutagenesis data show that amino acid residues in the membrane-proximal C-tail and base of TM1 are necessary for hM 1 receptors to achieve a transport-competent state.
( 332 VSSELRSLL 340 ) (Krause et al., 2000) . , or L 340 in this motif caused ER retention of the receptor (Krause et al., 2000; Thielen et al., 2005) . The membrane-permeable V 2 receptor antagonist SR121463B rescued the plasma membrane expression (Thielen et al., 2005) , suggesting that the mutant V 2 receptor could not achieve a transport-competent conformation (Krause et al., 2000; Thielen et al., 2005) . Perhaps the F(x) 6 LL motif is another type of folding motif that mediates transport-competent folding necessary for many GPCRs to exit the ER and enter the secretory pathway.
All five subtypes of the muscarinic receptor also possess an F(x) 6 LL motif. In the M 1 sequence, this motif, 423 FRDTFRLLL 431 , is analogous to the h(x) 3 h(x) 2 hh (   423   FRDTFRLLL   431 ) motif described by Krause and coworkers (2000) . Using site-directed mutagenesis, we investigated the role of the F(x) 6 LL motif in the human M 1 muscarinic receptor (hM 1 ). We found that mutation of the F and L residues in the motif caused retention of the mutant hM 1 receptor in the ER and a consequent loss of plasma membrane expression. The membrane-permeable muscarinic antagonist atropine, but not the quaternary antagonist NMS, restored the plasma membrane expression and signaling of the mutant receptor. Our data indicate that amino acids in the F(x) 6 LL motif are necessary for the ER export of the M 1 receptor.
Materials and Methods
Receptor Mutagenesis and Constructs. The hM 1 receptor cDNA, cloned into a modified Okayma-Berg expression vector (pCD), was provided by Dr. Tom I. Bonner at the National Institute of Mental Health. Mutant hM 1 receptors were made by introducing point mutations into the hM 1 receptor cDNA of pCDhM 1 by use of the QuikChange II Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA) and mutagenesis primers. All receptor mutants were sequenced at the Oklahoma State University core DNA-sequencing facility to verify the presence of the planned mutation and to ensure that no other mutations were acquired during PCR.
To make GFP-tagged wild-type, hM , and hM 1AA46 -47 receptor constructs, the sequences encoding wild-type (Bonner et al., 1988) , hM , and hM receptors were amplified by use of the 20-cycle PCR reaction and primers with 5Ј EcoRI (5Ј-GCAGAGGAATCCAACACTTCAGCCCCAC-3Ј; forward) and BamHI (5Ј-GCAGAGGGATCCTCAGCATTGGCGGGAG-3Ј; reverse) restriction sites. The PCR product was purified and digested with EcoRI and BamHI and ligated into pEGFP-C2 (Clontech, Mountain View, CA) digested with the same restriction enzymes. To ensure the translation of the receptor constructs in the ER, the pEGFP-C2 construct was modified to include a human growth hormone secretion signal sequence (amino acids Ϫ26 to Ϫ1 of human growth hormone) 5Ј of the sequence-encoding GFP (Volchuk et al., 2000) . This construct was used to express wild-type and mutant hM 1 receptors as N-terminal fusion proteins to GFP.
Cell Culture and Transient Transfections. CHO cells were subcultured every 2 to 3 days and were maintained in growth medium (F-12K supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin) in a humidified incubator set at 37°C in an atmosphere of 5% CO 2 /95% air. In preparation for transient transfections, CHO cells were trypsinized and plated in a 24-well plate format at 1.65 ϫ 10 5 cells per well in 500 l of transfection medium (F-12K supplemented with 10% fetal bovine serum). On the next day, cells were transfected by use of Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the product protocol. In brief, 19.2 g of plasmid DNA/plate was incubated in 1200 l of Opti-MEM I (Invitrogen) for 5 min at room temperature. In a separate tube, Lipofectamine 2000 (48 l/plate) was incubated in 1200 l of Opti-MEM I for 5 min at room temperature. The DNA and lipid mixtures were combined into a single tube and mixed gently. The lipid complexes were allowed to form during a 20-min incubation at room temperature. Complexes (100 l/well) were added to each well of a 24-well plate, and the plate was placed into a humidified incubator. After a 6-h incubation, medium was replaced in each well with fresh transfection medium (500 l). Cells were incubated for an additional 18 h (24 h total) in a humidified incubator before conducting experiments.
Characterization To determine the effect of atropine on the plasma membrane expression of wild-type and mutant receptors, CHO cells were incubated with either a single concentration of atropine (0.1 M) or increasing concentrations of atropine (0.5 log unit) in transfection medium for 18 h beginning 6 h after transfecting cells with either wild-type or mutant hM 1 receptor constructs. To remove atropine, cells were washed three times with F-12K (500 l) with a 20-min incubation between each wash in a humidified incubator set at 37°C in an atmosphere of 5% CO 2 /95% air. Cells were then used in intact, whole-cell We also determined the effect of short-term atropine treatment on the plasma membrane expression of wild-type and hM 1AA430 -431 receptors. In brief, CHO cells were transiently transfected with wild-type hM 1 or hM 1AA430 -431 receptor constructs as described under Cell Culture and Transient Transfections. Cells were washed three times with F-12K (500 l) to remove serum and then incubated with atropine (0.1 M) for various periods of time for up to 7 h. To remove atropine, CHO cells were washed three times with F-12K (500 l), with a 20-min incubation between each wash in a humidified incubator set at 37°C in an atmosphere of 5% CO 2 /95% air. Cells were then used in intact, whole-cell [ 3 H]NMS binding assays as described under Receptor Binding Assays. In some experiments, CHO cells expressing either wild-type hM 1 , hM , hM , or hM 1A46,A431 were incubated in the absence and presence of N-methylscopolamine (0.2 M) or scopolamine (0.5 M) for various periods of time for up to 7 h. Cells were washed as described above and used in intact, whole-cell [ 3 H]NMS binding assays as described under Receptor Binding Assays.
To determine whether hM 1AA430 -431 receptors were stably expressed on the plasma membrane after atropine-treatment, CHO cells were incubated with atropine (0.1 M) for 18 h beginning 6 h after transfection with wild-type and hM 1AA430 -431 receptors. Atropine-treated cells were washed three times with F-12K (500 l), with a 20-min incubation between each wash in a humidified incubator. After the third and final wash, cells were incubated for various periods of time for up to 8 h in a humidified incubator set at 37°C in an atmosphere of 5% CO 2 /95% air, then used in intact, whole- (Griffin et al., 2003) , and radioactivity was counted by use of a Beckman LS 6500 scintillation counter.
To (Griffin et al., 2003) , and radioactivity was counted by use of a Beckman LS6500 scintillation counter.
The average amount of protein expressed in CHO cells was determined for each radioligand-binding assay performed, and specific [ 3 H]NMS or [ 3 H]QNB binding was normalized to the amount of protein measured. In brief, three wells of a 24-well plate were plated and transfected for each receptor construct and assay condition as described under Cell Culture and Transfections at the same time as experimental plates. The cells were washed two times with 500 l of mannitol wash buffer [0.29 M mannitol, 0.01 M Tris, 0.5 mM Ca(NO 3 ) 2 , pH 7.4] to remove serum. The protein concentration was determined for each well using the bicinchoninic acid protocol as described previously (Goldschmidt and Kimelberg, 1989) .
Phosphoinositide Hydrolysis Assays. Phosphoinositide hydrolysis assays were conducted on CHO cells transiently expressing wild-type and mutant hM 1 receptors as described previously (Sawyer et al., 2006 3 H]Inositol phosphates were extracted from cells by adding 200 l of perchloric acid (5%) to each well and incubating the plate for 15 min on ice. The extracts were neutralized by adding 187 l of 0.525 M KOH containing 10 mM Tris to each well of the plate, followed by a 15-min incubation on ice. Neutralized extracts were pipetted into individual 1.5-ml tubes, and wells were washed with 400 l of 25 mM Tris, pH 7.4, which was added to the appropriate tube. Tubes were centrifuged at 3000g for 10 min and the supernatant was transferred into glass tubes containing 2 ml of 25 mM Tris, pH 7.4. The solution was applied to a 1-ml column of Dowex AG 1-X8 (formate form, 100 -200 mesh). Columns were washed with water (4 ϫ 4 ml) and eluted into 25-ml scintillation vials with 2.5 ml of 1 M ammonium formate, 0.1 M formic acid. Scintiverse (20 ml) was added, and the radioactivity was counted with a Beckman LS 6500 scintillation counter.
In some experiments, CHO cells were incubated with atropine (0.1 M) for 18 h beginning 6 h after transfection with wild-type or hM 1AA430 -431 receptor constructs. The atropine-containing medium was replaced with F-12K medium (500 l) containing atropine (0.1 M) and myo-[ 3 H]inositol (0.2 M, PerkinElmer Life and Analytical Sciences). Cells were incubated for 18 h in a humidified incubator, then washed three times with F-12K (500 l) with a 20-min incubation between each wash in a humidified incubator. Cells were then used in phosphoinositide hydrolysis assays as described above.
Epifluorescence Images. CHO cells were plated at 0.25 ϫ 10 5 cells/well on poly(D-lysine)-treated plates in transfection medium (500 l) and placed into a humidified incubator at 37°C in an atmosphere of 5% CO 2 /95% air. On the next day, cells were cotransfected with pEGFP-C2-hM 1 (0.2 g/well), pEGFP-C2-hM 1AA46 -47 (0.2 g/well), pEGFP-C2-hM 1AA430 -431 (0.2 g/well), or pEGFP-C2-hM 1A46,A431 and pDsRed2-ER (0.2 g/well) (Clon- , and the concentration of carbachol eliciting half-maximal response (EC 50 ) were estimated from phosphoinositide hydrolysis data by use of nonlinear regression analysis according to a logistic equation as described by Bowen and Jerman (1995) . The same equation was used to estimate the Hill slope, E max , and EC 50 of atropinemediated plasma membrane expression of hM 1AA430 -431 receptors (Bowen and Jerman, 1995) . The operational model (Black et al., 1985) was used to analyze agonist-induced phosphoinositide hydrolysis to obtain a relative estimate of the plasma membrane expression of mutant M 1 receptors. The following equation was fitted to the concentration-response curves by use of nonlinear regression analysis:
In this equation, y denotes the response, X denotes the concentration of agonist, M sys represents the maximum response of the system, n represents the transducer slope factor, and K obs denotes the observed dissociation constant of the agonist. The parameter is proportional to receptor expression (R T ) and the intrinsic efficacy of the agonist (ε) and inversely proportional to the sensitivity of the signaling cascade (K E ):
The data for agonist-stimulated phosphoinositide hydrolysis by wild-type and mutant M 1AA430 -431 receptors were fitted simultaneously to eq. 1, sharing the estimates of M sys , K obs , and n between the curves and obtaining unique estimates of (GraphPad Prism, version 4.03; GraphPad Software Inc., La Jolla, CA) for each receptor. If the intrinsic efficacy of the agonist is the same at both wildtype and mutant receptors, then the estimate of for the mutant receptor ( mut ), expressed relative to that of the wild-type receptor ( WT ) is equivalent to the corresponding ratio of receptor densities on the plasma membrane:
The significance of differences between sets of data were calculated by use of either Student's t tests (two-tailed) or an one-way ANOVA with Dunnett's post hoc test (GraphPad Prism).
Results
Epifluorescence Microscopy. Because the F(x) 6 LL motif is known to be involved in the ER export of GPCRs (Duvernay et al., 2004 (Duvernay et al., , 2005 (Duvernay et al., , 2009 , we examined how mutagenesis of the motif affected the cellular distribution of the hM 1 receptor relative to the ER marker DsRed-ER by use of epifluorescence microscopy. As shown in Fig. 1A , GFP-tagged wild-type hM 1 receptors did not colocalize with DsRed-ER and exhibited a distribution consistent with expression on the plasma membrane. In contrast, GFP-tagged receptors containing two L to A point mutations in the adjacent, C-terminal leucines of the F(x) 6 LL motif (GFP-tagged hM 1AA430 -431 ) colocalized with DsRed-ER (Fig. 1C) . Treatment with atropine (0.1 M) for 18 h had little effect on the distribution of the wild-type receptor, but converted the distribution of the hM mutant into that of the wild-type receptor (Fig. 1, B and D) .
Receptors for amine neurotransmitters within the rhodopsin class contain a highly conserved aspartic acid in TM3 (D 105 in the M 1 sequence) that is thought to form a counter ion for the amine moiety of the neurotransmitter (Spalding et al., 1994; Page et al., 1995) . The D105N point mutant of the hM 1 receptor has greatly reduced affinity for acetylcholine, [ 3 H]NMS and other orthosteric ligands (Page et al., 1995) . We examined how introducing the D105N mutation into the GFP-tagged hM 1AA430 -431 mutant (GFP-tagged hM ) affected the ability of atropine to rescue receptor expression on the plasma membrane. The D105N mutation of the wild-type receptor (GFP-tagged hM 1N105 ) had no detectable effect on cellular localization in the absence or presence of atropine (Fig. 2, A and B). Although the GFP-tagged hM 1N105AA430 -431 mutant had a distribution similar to that of hM , its distribution was unaffected by 18-h atropine (0.1 M) treatment (Fig. 2 , C and D). Our results show that the hM 1AA430 -431 mutant is probably trapped in the ER and that the binding of atropine to the orthosteric binding site can rescue its expression on the plasma membrane.
In the vasopressin V2 receptor, the F(x) 6 LL motif exists in an amphipathic ␣-helix referred to as helix 8 (Thielen et al., 2005) . The C-terminal leucines of the F(x) 6 LL motif (L 339 and L 340 ) of V2 receptors may interact with residues at the base of TM1 (Thielen et al., 2005) . We were interested in determining, therefore, whether hM 1 receptors containing mutations at the base of TM1 (hM ) associate with the ER in a manner similar to that of hM . Figure 2 shows that the GFPtagged hM 1AA46 -47 mutant is distributed within the ER and that incubation with atropine (0.1 M) for 18 h rescues its expression on the plasma membrane (Fig. 2, E and F ). This effect of atropine is abolished in the corresponding D105N mutant (GFP-tagged hM 1N105AA46 -47 ) (Fig. 2, G and H) . (Fig. 4A ). Atropine caused a concentration-dependent increase in binding. The maximal effect was an 8.6-fold increase in binding, and the half-maximal effect occurred at a negative log atropine concentration (pEC 50 ) of 7.97 Ϯ 0.11.
Twenty-four hours after transfection, CHO cells tran- (Fig. 4B) . Binding increased 3.3-fold after 7 h of treatment with atropine. The initial rate of delivery of the hM 1AA430 -431 receptor to the plasma membrane was estimated to be 115 Ϯ 6 fmol/mg protein per hour from the slope of the plot of binding versus time. In contrast, atropine (0.1 M) only caused a 1.1-fold increase in binding to the wild-type receptor over the 7-h period (data not shown).
We also measured the decay of binding to the hM 1AA430 -431 receptor after removal of atropine (0.1 M) after an 18-h incubation with it (Fig. 4C) . Binding appeared stable for 1.5 h (709 Ϯ 57 fmol/mg protein), but then gradually declined 36% 8 h after removal of atropine (455 Ϯ 28 fmol/mg protein). In CHO cells expressing the wild-type hM 1 receptor, [
3 H]NMS binding was not significantly different from control (932 Ϯ 130 fmol/mg protein) 8 h after atropine washout (878 Ϯ 126 fmol/mg protein). We fitted an exponential decay equation to the data in Fig. 4C , assuming that the equilibrium level (i.e., plateau level) of receptor expression is equivalent to that measured in Fig. 3B (i.e., 162 Ϯ 13 fmol/mg protein). The estimate of the rate constant for loss of hM 1AA430 -431 was 0.09 Ϯ 0.0002 h Ϫ1 . To investigate whether atropine is binding to receptors inside the cell (presumably in the ER) to rescue expression on the plasma membrane, we compared the effects of atropine with those of two close structural analogs, scopolamine and NMS. Like atropine, scopolamine readily penetrates the plasma membrane, whereas its N-methyl derivative (NMS) does not. After a 7-h incubation with scopolamine (0. (Fig. 6) , and hM 1A46,A431 receptor mutants were only 4.6, 11.8, and 9.8% of wild type, respectively (Fig. 6) . Treatment with atropine (0.1 M) for 18 h caused 12.4-, 5.7-, and 6.6-fold increases, respectively in [ 3 H]QNB binding to the receptor mutants (Fig. 6) ) described by Krause and co-workers (2000) . To explore the role of this hM 1 motif further, we made point mutations in the F and L residues of the consensus sequences and determined the consequences on receptor expression at the plasma membrane. Figure 7A shows Fig. 7A and Table 3) .
We also further investigated the plasma membrane expression of receptors containing mutations in residues at the base of TM1 (Fig. 7B) Table  3 ). Binding to the double mutant, hM , was greatly reduced relative to wild type (2.1%) as described above (Fig.  3C ). Atropine treatment (0.1 M, 18 h) restored binding to all of the mutants ( Fig. 7B and Table 3 ).
In the homology model of the V2 vasopressin receptor, the terminal leucines ( 430 LL 431 ) of the F(x) 6 LL motif may interact with adjacent hydrophobic residues at the base of TM 1 (Thielen et al., 2005) . This interaction is thought to be necessary for the transport-competent folding of the receptor. Disruption of this interaction in the hM 1AA46 -47 or hM 1AA430 -431 mutants could explain the large loss of atropinerescuable receptor expression on the plasma membrane. We investigated, therefore, whether the trans-mutations (hM 1A46,A431 and hM 1A47,A430 ) caused atropine-restorable deficits of receptor expression on the plasma membrane comparable with those of the cis-mutations (hM 1AA46 -47 and hM 1AA430 -431 ). As shown in Fig. 7C (see also Fig. 3D for hM 1A46,A431 ), the [ 3 H]NMS binding values for hM 1A46,A431 and hM 1A47,A430 were greatly reduced relative to wild type (7.1 and 1.2%, respectively) and comparable with those of hM 1AA46 -47 (2.1%) and hM . In contrast, specific binding to the double mutant hM 1A48,A431 was similar to that of the single mutant hM 1A431 , suggesting that 48 I is not involved in an interaction with the F(x) 6 LL motif and that the interaction is specific to 46 VL 47 at the base of TM1. After atropine treatment (0.1 M, 18 h), [ The effect of NMS and scopolamine on the plasma membrane expression of wild-type and mutant hM 1 receptors hM 1A46,A431 , hM 1A47,A430 and hM 1A48,A431 was greatly restored (Fig. 7C) .
Agonist-Stimulated Phosphoinositide Hydrolysis. We measured carbachol-stimulated phosphoinositide hydrolysis in CHO cells expressing hM to determine whether the loss of function was similar to the loss of the receptor expression on the plasma membrane. Figure 8 shows carbachol-stimulated phosphoinositide hydrolysis in CHO cells expressing the wild-type hM 1 receptor and hM . The pEC 50 and E max values of carbachol were both less for the hM 1AA430 -431 mutant (4.70 Ϯ 0.06 and 6.9-fold above basal, respectively) compared with wild type (5.62 Ϯ 0.11 and 8.6-fold above basal, respectively) ( Table 4) . We fitted the operational model (Black et al., 1985) to the data sharing the estimate of the dissociation constant of carbachol between the curves and estimating values of for each curve. This parameter is proportional to the density of functional receptors. The estimate of Ϯ S.E.M. for the data obtained with the hM 1AA430 -431 mutant was 10.2 Ϯ 1.2% of wild type, which agrees with the B max value of [ 3 H]NMS in this mutant relative to wild type (8.2%). Atropine treatment (0.1 M, 18 h) partially prevented the loss in function in the hM 1AA430 -431 mutant relative to wild type (one third the potency of wild type, no change in E max ). Analysis with the operational model gave an estimate of that was 43% of wild type, which is similar to the estimate of the B max of [ 3 H]NMS relative to wild type (63%). 
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The estimate of the negative log dissociation constant of carbachol was 4.07 Ϯ 0.29. (1 mM) by wildtype hM 1 receptors in untreated cells (9.5 Ϯ 1.3-fold over basal) was not significantly different from that obtained in atropine-treated cells (0.1 M, 18 h) (8.9 Ϯ 1.5-fold over basal).
Discussion
The effect of atropine on the expression of hM and the other mutants is caused by its binding to the orthosteric site of the receptor because its EC 50 value for affecting expression exhibits high potency (i.e., 10 nM) and is within the range of that expected for a specific muscarinic effect. In addition, atropine's effect was prevented by the mutation D105N in the receptor, which is known to disrupt the binding of muscarinic agonists and antagonists. It might be expected that the rescuing effect of atropine on receptor expression should be proportional to receptor occupancy by atropine, in which case the EC 50 value for rescuing expression should be similar to the dissociation constant of atropine for hM receptors in the ER. It is known that atropine binds to the wild-type hM 1 receptor with a dissociation constant of 1 nM, which represents 10-fold higher affinity than the EC 50 value for rescuing expression of hM . We speculate that, in the ER, the hM 1AA430 -431 mutant exists primarily in a conformation exhibiting low affinity for atropine and that atropine selects for the high-affinity wild-type conformation that is required for ER export.
It is known that high-affinity ligands often stabilize their respective binding proteins and inhibit their degradation. If it is assumed that hM 1AA430 -431 and the other mutants are rapidly degraded within the ER and that atropine inhibits The effects of mutating amino acid residues in the F(x) 6 LL motif and at the base of TM1 on the plasma membrane expression of hM 1 receptors as determined by intact, whole-cell ͓ this degradation, then this mechanism could explain the atropine-induced increase in receptor expression on the plasma membrane. However, upon atropine treatment, we found that hM 1AA430 -431 receptors appeared on the plasma membrane at an initial rate of 115 Ϯ 6 fmol/mg protein per hour (see Fig. 4 ). Dividing this rate by the maximal receptor expression after 18 h of atropine treatment yields a rate constant of 0.12 h Ϫ1 . Using RPD regulated secretion/aggregation technology at low hM 1 receptor expression, we previously estimated an initial rate of delivery of the wild-type hM 1 receptor to the plasma membrane of 18 fmol/mg protein per hour (Sawyer et al., 2006) . When normalized relative to receptor expression at 18 h, the rate constant for ER export of the wild-type receptor (0.10 h Ϫ1 ) is approximately the same as that of hM . If the hM 1AA430 -431 receptor were rapidly degraded in the ER, then its initial atropine-induced rate of expression should be much less than the rate of delivery of the wild-type receptor to the plasma membrane. The similarity in the rates suggests that atropine acts by binding to a substantial pool of hM 1AA430 -431 and enabling ER export and not by preventing receptor degradation.
It might also be argued that atropine stabilizes hM 1AA430 -431 on the plasma membrane and inhibits its endocytosis and ultimate degradation, leading to an increase in expression on the plasma membrane. We found, however, that the rate constant for the internalization of the hM 1AA430 -431 receptor after atropine washout (0.09 h Ϫ1 ; Fig. 4 ), was similar to that (0.07 h Ϫ1 ) estimated for the wild-type hM 1 receptor by use of RPD regulated secretion/aggregation technology (Sawyer et al., 2006) . The similarity between the two estimates shows that the atropine-rescued hM 1AA430 -431 receptor exhibits stability comparable with that of the wild-type hM 1 receptor, and that the effect of atropine cannot be attributed to prevention of receptor internalization and degradation. The hM 1AA430 -431 mutant behaves differently from M 2 and M 3 muscarinic receptors bearing a N6.58Y mutation that causes internalization and constitutive activation in an atropinereversible manner (Dowling et al., 2006; Nelson et al., 2006) .
Our results showed that alanine mutagenesis of single residues in the consensus sequence (h(x) 3 h(x) 2 hh) within the C terminus of hM 1 caused a moderate reduction in plasma membrane expression (approximately 50%), whereas the double-point mutations cause a substantial decline (Ͼ90%) in expression. The additive effect of the point mutations suggests that the motif consists of a concatenation of residues, each contributing to the stabilization of the transportcompetent conformation of the receptor.
We also found that alanine mutagenesis of critical residues at the base of TM1 had consequences on receptor expression analogous to those of mutations within the F(x) 6 LL motif. In the ␤ 2 -adrenoceptor structure Rosenbaum et al., 2007; Duvernay et al., 2009 ) and the homology model of Thielen and co-workers (2005) , the F(x) 6 LL motif forms an ␣-helical structure that interacts with residues at the base of TM1. It is possible that the proper folding of the hM 1 receptor requires the interaction of the F(x) 6 LL motif with critical hydrophobic residues at the base of TM1. Our results suggest that alanine mutagenesis of either locus disrupts this interaction and prevents the transport-competent folding of the receptor. We cannot rule out the possibility, however, that the two motifs act independently to promote receptor folding.
We are not the only group to observe a ligand-induced rescue in the plasma membrane expression of a GPCR with a folding mutation. Thielen and co-workers (2005) showed that the membrane-permeable vasopressin V 2 receptor antagonist SR121463B rescues the plasma membrane expression of a V 2 receptor mutant possessing mutations similar to that of hM 1AA430 -431 receptors (i.e., V 2 receptor, L339T/L340T). They postulated, based on the observations of Wü ller and co-workers (2004) , that the SR121463B rescues the plasma membrane expression of the mutant V 2 receptor by binding to it, causing the mutant receptor to fold adequately to exit the ER (Thielen et al., 2005) . In addition, alanine mutagenesis of some highly conserved residues in TM domains 2, 3, 4, 6, and 7 of the hM 1 receptor greatly reduces receptor expression, and treatment with atropine (1 M) for 24 h has been shown to rescue expression (Hulme et al., 2003) . These residues are thought to be involved in intermolecular interactions that stabilize the receptor.
Our binding experiments with the membrane-permeable muscarinic antagonist radioligand [ 3 H]QNB (1.6 nM) showed little binding to the hM 1AA430 -431 mutant after an 18-h incubation at a temperature (4°C) that prevents receptor trafficking. A simple explanation is that at 4°C [ 3 H]QNB occupies few misfolded receptors at a concentration of 1.6 nM, because of its low affinity for the misfolded receptor, and possibly because isomerization of the unfolded receptor to the folded state may be inhibited at this low temperature. It is unlikely that the hM 1AA430 -431 mutant is rapidly degraded in the ER because of the substantial fluorescence of the fusion protein associated with the ER. In addition, the substantial rate of delivery of the fusion protein after atropine treatment implies a large pre-existing pool of rescuable receptor in the ER as described above.
Once the hM 1AA430 -431 mutant reaches the plasma membrane, it seems to function as well as the wild-type receptor in terms of agonist stimulation of phosphoinositide hydrolysis. Our analysis of the concentration-response curves of carbachol for eliciting phosphoinositide hydrolysis in CHO cells transfected with the wild-type receptor or hM showed that the data could be attributed entirely to changes in the -parameter of the operational model. The value of this parameter is proportional to receptor expression and intrinsic efficacy and inversely proportional to the sensitivity of the signaling cascade (eq. 2). Because the estimate of for the hM 1AA430 -431 mutant expressed relative to that of the wildtype receptor was approximately the same as the corresponding relative B max values for [ 3 H]NMS, our data show that the loss of function displayed by the mutant can be attributed to decreased expression on the plasma membrane and not to a loss in affinity or efficacy.
The stability of hM 1AA430 -431 on the plasma membrane suggests that it might be a useful construct for investigating receptor trafficking. In cells expressing the mutant, a pulse of properly folded receptor can be synchronously released from the ER with a period of atropine treatment. The fate of these receptors can be observed by use of fluorescence microscopy (with a GFP-tagged receptor) or [ 3 H]NMS binding (plasma membrane expression) to investigate receptor trafficking (i.e., plasma membrane delivery, internalization, recycling, and degradation) without interference from constitutively expressed receptor. Similar approaches have been described with use of thermoreversible folding mutants (Hirschberg et al., 1998) and RPD Regulated Secretion/Aggregation technology (Sawyer et al., 2006) . Naturally occurring mutations in certain GPCRs are implicated in causing the ER retention of these receptors and, thus, causing human disease (Duvernay et al., 2005) . The effect of atropine on the expression of hM 1AA430 -431 receptors suggests that membrane-permeable ligands may be useful in rescuing the plasma membrane expression of certain misfolded GPCRs that are retained in the ER. Our results with the hM 1AA430 -431 mutant show that atropine treatment rescues expression and that the rescued receptor has a stability and functional activity equivalent to the wild-type receptor. The identification of novel membrane-permeable muscarinic receptor ligands that stabilize the receptor by binding to allosteric sites that do not interfere with orthosteric ligand signaling may represent a useful therapeutic strategy for rescuing misfolded mutants.
